PMID- 20677212
OWN - NLM
STAT- MEDLINE
DCOM- 20110407
LR  - 20191210
IS  - 1099-1263 (Electronic)
IS  - 0260-437X (Linking)
VI  - 31
IP  - 1
DP  - 2011 Jan
TI  - Inter-laboratory validation of the modified murine local lymph node assay based 
      on 5-bromo-2'-deoxyuridine incorporation.
PG  - 63-74
LID - 10.1002/jat.1567 [doi]
AB  - The murine local lymph node assay (LLNA) is a well-established alternative to the 
      guinea pig maximization test (GPMT) or Buehler test (BT) for the assessment of 
      the skin sensitizing ability of a drug, cosmetic material, pesticide or 
      industrial chemical. Instead of radioisotope using in this method, Takeyoshi M. 
      et al. (2001) has developed a modified LLNA based on the 5-bromo-2'-deoxyuridine 
      (BrdU) incorporation (LLNA:BrdU-ELISA). The LLNA:BrdU-ELISA is practically 
      identical to the LLNA methodology excluding the use of BrdU, for which a single 
      intraperitoneal injection of BrdU is made on day 4, and colorimetric detection of 
      cell turnover. We conducted the validation study to evaluate the reliability and 
      relevance of LLNA:BrdU-ELISA. The experiment involved 7 laboratories, wherein 10 
      chemicals were examined under blinded conditions. In this study, 3 chemicals were 
      examined in all laboratories and the remaining 7 were examined in 3 laboratories. 
      The data were expressed as the BrdU incorporation using an ELISA method for each 
      group, and the stimulation index (SI) for each chemical-treated group was 
      determined as the increase in the BrdU incorporation relative to the concurrent 
      vehicle control group. An SI of 2 was set as the cut-off value for exhibiting 
      skin sensitization activity. The results obtained in the experiments conducted 
      for all 10 chemicals were sufficiently consistent with small variations in their 
      SI values. The sensitivity, specificity, and accuracy of LLNA:BrdU-ELISA against 
      those of GPMT/BT were 7/7 (100%), 3/3 (100%), and 10/10 (100%), respectively.
CI  - Copyright (c) 2010 John Wiley & Sons, Ltd.
FAU - Kojima, Hajime
AU  - Kojima H
AD  - National Institute of Health Sciences, Tokyo, Japan. h-kojima@nihs.go.jp
FAU - Takeyoshi, Masahiro
AU  - Takeyoshi M
FAU - Sozu, Takashi
AU  - Sozu T
FAU - Awogi, Takumi
AU  - Awogi T
FAU - Arima, Kazunori
AU  - Arima K
FAU - Idehara, Kenji
AU  - Idehara K
FAU - Ikarashi, Yoshiaki
AU  - Ikarashi Y
FAU - Kanazawa, Yukiko
AU  - Kanazawa Y
FAU - Maki, Eiji
AU  - Maki E
FAU - Omori, Takashi
AU  - Omori T
FAU - Yuasa, Atsuko
AU  - Yuasa A
FAU - Yoshimura, Isao
AU  - Yoshimura I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
PL  - England
TA  - J Appl Toxicol
JT  - Journal of applied toxicology : JAT
JID - 8109495
RN  - 0 (Organic Chemicals)
RN  - G34N38R2N1 (Bromodeoxyuridine)
SB  - IM
MH  - Animals
MH  - Bromodeoxyuridine/*metabolism
MH  - Dermatitis, Allergic Contact/diagnosis/etiology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Laboratories
MH  - *Local Lymph Node Assay
MH  - Mice
MH  - Mice, Inbred CBA
MH  - Organic Chemicals/*analysis/toxicity
MH  - Quality Control
MH  - Random Allocation
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2010/08/03 06:00
MHDA- 2011/04/08 06:00
CRDT- 2010/08/03 06:00
PHST- 2010/08/03 06:00 [entrez]
PHST- 2010/08/03 06:00 [pubmed]
PHST- 2011/04/08 06:00 [medline]
AID - 10.1002/jat.1567 [doi]
PST - ppublish
SO  - J Appl Toxicol. 2011 Jan;31(1):63-74. doi: 10.1002/jat.1567.